Research & Development
Biogen proposes to buy Sage’s remaining stake in a $442 million deal
Biogen is navigating the slow pace of sales of its Alzheimer’s drug Lacambi in the United States after concerns about ...
US FDA expands J&J’s psoriasis drug for inflammatory bowel disease, ET HealthWorld
By Sriparna Roy and Bhanvi Satija LONDON: The US Food and Drug Administration has approved Johnson & Johnson’s drug Tremfya ...
Eli Lilly invests $1.8 billion in Irish sites to ramp up production of Alzheimer’s, obesity drug, ET HealthWorld
LONDON: Eli Lilly is investing $1.8 billion in two manufacturing sites in Ireland to boost production of its wildly popular ...
Kiran Mazumdar-Shaw calls for innovation-driven value creation in India’s biotech sector, ET Healthworld
New Delhi: Biocon Chairperson Kiran Mazumdar-Shaw on Thursday called for more investment in research and development and promoting a culture ...
Panacea Biotech gets $20 million loan from US government to expand hexavalent vaccine capacity, ET HealthWorld
New Delhi: Panacea Biotec on Thursday said the US International Development Finance Corporation (DFC), has agreed to provide the company ...
Alchem ​​joins race for $3 billion for JB Chem as Torrent stalls talks, ET HealthWorld
New Delhi: Alkem Laboratories Ltd, India’s fifth-largest branded pharmaceutical company, has joined the race to JB Chemicals and Pharmaceuticals as ...
Neurocrine halts schizophrenia drug development as trial fails, ET HealthWorld
LONDON: Neurocrine Biosciences said on Thursday it will halt development of its experimental drug, which aims to improve cognitive function ...
Bavarian Nordic sees potential to increase ampox vaccine capacity, ET HealthWorld
Copenhagen: Bavarian Nordic said on Thursday it could supply 13 million doses of its mpox vaccine by the end of ...
Moderna prepares plan to cut research and development costs, ET HealthWorld
Washington: Shares of Moderna tumbled early on Thursday after the vaccine developer said it was cutting research and development spending ...
Moderna forecasts sales decline next year, shares near four-year low, ET HealthWorld
By Patrick Wingrove LONDON: Moderna on Thursday pushed back its break-even goal by two years as it delayed the timeline ...